OBJECTIVE: CYP3A5, MDR1 (ABCB1), and OATP1 (SLCO1B1) polymorphisms have been associated with variability in the pharmacokinetics (PK) of protease inhibitors. The aim of this study was to investigate the influence of CYP3A5 A6986G, ABCB1 (C3435T and G2677T), and SLCO1B1 (T521C and A388AG) polymorphisms on the PK and virologic outcome of lopinavir/ritonavir (LPV/RTV) in HIV-infected children. DESIGN AND METHODS: We conducted a prospective cohort study in children (4-18 years old) on stable antiretroviral therapy with LPV/RTV. CYP3A5, ABCB1, and SLCO1B1 genotypes were determined using polymerase chain reaction amplification with allelic discrimination assays. The 12-hour plasma area under the concentration-time curves (AUC) and clearances (CL) of LPV and RTV were estimated using noncompartmental models. HIV RNA viral load was evaluated every 12 weeks for a total study period of 52 weeks. Analysis of covariance models with adjustment for age and adherence and allometric adjustment of CL were used to assess associations between studied polymorphisms and AUC, CL, and HIV RNA. RESULTS: Fifty children (median age 11.2 years) were enrolled. Allele frequencies of the genotypes studied were in Hardy-Weinberg equilibrium. There was no statistically significant association between LPV or RTV AUC or CL, and CYP3A5, ABCB1, or SLCO1B1 A388G polymorphisms. There was a significant association between SLCO1B1 T521C genotype and increased LPV AUC (P = 0.042) and a nearly significant association with decreased LPV CL (P = 0.063). None of the studied polymorphisms, including SLCO1B1 T521C, were associated with virologic outcome during 52 weeks of study follow-up. CONCLUSIONS: There was no statistically significant influence of the CYP3A5, ABCB1, or SLCO1B1 A388AG polymorphisms on the PK and virologic outcome of LPV/RTV in HIV-infected children. SLCO1B1 T521C polymorphism was significantly associated with an increase in LPV AUC but was not associated with undetectable HIV RNA during the study period.
OBJECTIVE:CYP3A5, MDR1 (ABCB1), and OATP1 (SLCO1B1) polymorphisms have been associated with variability in the pharmacokinetics (PK) of protease inhibitors. The aim of this study was to investigate the influence of CYP3A5A6986G, ABCB1 (C3435T and G2677T), and SLCO1B1 (T521C and A388AG) polymorphisms on the PK and virologic outcome of lopinavir/ritonavir (LPV/RTV) in HIV-infectedchildren. DESIGN AND METHODS: We conducted a prospective cohort study in children (4-18 years old) on stable antiretroviral therapy with LPV/RTV. CYP3A5, ABCB1, and SLCO1B1 genotypes were determined using polymerase chain reaction amplification with allelic discrimination assays. The 12-hour plasma area under the concentration-time curves (AUC) and clearances (CL) of LPV and RTV were estimated using noncompartmental models. HIV RNA viral load was evaluated every 12 weeks for a total study period of 52 weeks. Analysis of covariance models with adjustment for age and adherence and allometric adjustment of CL were used to assess associations between studied polymorphisms and AUC, CL, and HIV RNA. RESULTS: Fifty children (median age 11.2 years) were enrolled. Allele frequencies of the genotypes studied were in Hardy-Weinberg equilibrium. There was no statistically significant association between LPV or RTV AUC or CL, and CYP3A5, ABCB1, or SLCO1B1A388G polymorphisms. There was a significant association between SLCO1B1T521C genotype and increased LPV AUC (P = 0.042) and a nearly significant association with decreased LPV CL (P = 0.063). None of the studied polymorphisms, including SLCO1B1T521C, were associated with virologic outcome during 52 weeks of study follow-up. CONCLUSIONS: There was no statistically significant influence of the CYP3A5, ABCB1, or SLCO1B1A388AG polymorphisms on the PK and virologic outcome of LPV/RTV in HIV-infectedchildren. SLCO1B1T521C polymorphism was significantly associated with an increase in LPV AUC but was not associated with undetectable HIV RNA during the study period.
Authors: Zabrina L Brumme; Winnie W Y Dong; Keith J Chan; Robert S Hogg; Julio S G Montaner; Michael V O'Shaughnessy; P Richard Harrigan Journal: AIDS Date: 2003-01-24 Impact factor: 4.177
Authors: Su-Jun Lee; Khawja A Usmani; Brian Chanas; Burhan Ghanayem; Tina Xi; Ernest Hodgson; Harvey W Mohrenweiser; Joyce A Goldstein Journal: Pharmacogenetics Date: 2003-08
Authors: Gregory L Kearns; Susan M Abdel-Rahman; Sarah W Alander; Douglas L Blowey; J Steven Leeder; Ralph E Kauffman Journal: N Engl J Med Date: 2003-09-18 Impact factor: 91.245
Authors: John P Donahue; David Dowdy; Krishna K Ratnam; Todd Hulgan; James Price; Derya Unutmaz; Janet Nicotera; Steven Raffanti; Mark Becker; David W Haas Journal: Clin Pharmacol Ther Date: 2003-01 Impact factor: 6.875
Authors: David W Haas; Hulin Wu; Haihong Li; Ronald J Bosch; Michael M Lederman; Daniel Kuritzkes; Alan Landay; Elizabeth Connick; Constance Benson; Grant R Wilkinson; Harold Kessler; Richard B Kim Journal: J Acquir Immune Defic Syndr Date: 2003-11-01 Impact factor: 3.731
Authors: Ralf Winzer; P Langmann; M Zilly; F Tollmann; J Schubert; H Klinker; B Weissbrich Journal: Eur J Med Res Date: 2003-12-09 Impact factor: 2.175
Authors: Todd Hulgan; John P Donahue; Charlene Hawkins; Derya Unutmaz; Richard T D'Aquila; Stephen Raffanti; Fred Nicotera; Peter Rebeiro; Husamettin Erdem; Melissa Rueff; David W Haas Journal: J Acquir Immune Defic Syndr Date: 2003-10-01 Impact factor: 3.731
Authors: Becky Chandler; Lisa Almond; Jennifer Ford; Andrew Owen; Patrick Hoggard; Saye Khoo; David Back Journal: J Acquir Immune Defic Syndr Date: 2003-08-15 Impact factor: 3.731
Authors: Brookie M Best; Edmund V Capparelli; Huy Diep; Steven S Rossi; Michael J Farrell; Elaine Williams; Grace Lee; John N van den Anker; Natella Rakhmanina Journal: J Acquir Immune Defic Syndr Date: 2011-12-01 Impact factor: 3.731
Authors: Daniel H Johnson; Charles Venuto; Marylyn D Ritchie; Gene D Morse; Eric S Daar; Paul J McLaren; David W Haas Journal: Pharmacogenet Genomics Date: 2014-04 Impact factor: 2.089
Authors: Xinyan Zhang; Camlin Tierney; Mary Albrecht; Lisa M Demeter; Gene Morse; Robin DiFrancesco; Carrie Dykes; Hongyu Jiang; David W Haas Journal: Ther Drug Monit Date: 2013-04 Impact factor: 3.681
Authors: Juan Manuel De La Hoz; Laura Bolaño; Oriana Cárdenas; Robertulio González; José Sabbag; Lucy Palacio; Luz Marina Alonso; Homero San-Juan-Vergara; Guillermo Cervantes-Acosta Journal: Colomb Med (Cali) Date: 2014-12-30